Danaher (DHR) Seen Deftly Navigating AI Integration
Eagle Capital Management, an investment management company, released its second quarter 2026 investor letter. A copy of the letter can be downloaded here.
Danaher Corp (DHR)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Eagle Capital Management Boykin Curry | 9,361,490 | $1,783,176,557 | +43% | 5.45% |
| 2. | Generation Investment Management David Blood And Al Gore | 6,761,596 | $1,287,948,806 | -8% | 12.52% |
| 3. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 5,163,059 | $983,459,478 | +42% | 0.44% |
| 4. | Fisher Asset Management Ken Fisher | 4,484,774 | $854,260,080 | -3% | 0.25% |
| 5. | Holocene Advisors Brandon Haley | 3,592,798 | $684,356,163 | -12% | 1.54% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $247.89 | 100 | $24,789.00 | 3,256 | 2022-05-16 | Filing | |
| $247.89 | 100 | $24,789.00 | 3,256 | 2022-05-16 | Filing | |
| $221.46 | 900 | $199,314.00 | 3,156 | 2021-02-26 | Filing | |
| $221.46 | 900 | $199,314.00 | 3,156 | 2021-02-26 | Filing | |
| $221.59 | 4,800 | $1,063,632.00 | 2,409,190 | 2021-02-26 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $219.35 | 7,755 | $1,701,053.05 | 0 | 2026-08-21 | Filing | |
| $218.73 | 39,193 | $8,572,704.49 | 7,755 | 2026-08-21 | Filing | |
| $217.77 | 11,307 | $2,462,337.83 | 46,948 | 2026-08-21 | Filing | |
| $174.67 | 1,358 | $237,206.88 | 124,094 | 2026-05-01 | Filing | |
| $208.01 | 1,320 | $274,574.52 | 5,099 | 2026-02-19 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 55,084,630 | $10,492,520,322 | 0.16% | |
| 2. | 41,377,076 | $7,881,505,437 | 0.17% | |
| 3. | 29,540,895 | $5,626,949,757 | 0.24% | |
| 4. | 28,456,019 | $5,431,565,288 | 0.16% | |
| 5. | 16,316,834 | $3,108,030,541 | 0.54% |
News See All
Why Danaher (DHR) Remains a Healthcare Compounder to Watch
Aristotle Capital Management, LLC, an investment management company, released its "Value Equity Fund" Q2 2026 investor letter. A copy of the letter can be downloaded here.
Danaher vs. Intuitive Surgical: Is Recovery or Innovation the Better Long-Term Bet?
Healthcare investors often face a difficult decision when choosing between companies with very different paths to growth.
Danaher vs. Medtronic: Which Healthcare Recovery Story Has More Upside?
Healthcare investors are beginning to see signs of recovery across several parts of the industry, but not every recovery looks the same.
Could Danaher Corporation (DHR)’s Bioprocessing Recovery Give Bio-Rad Laboratories (BIO) Stock a Boost?
When biopharmaceutical suppliers report earnings, ripples move fast across the sector. On July 21, Danaher Corporation (NYSE:DHR) reported its Q2 2026 results.
Thermo Fisher (TMO) vs Danaher (DHR): Which Life Sciences Stock Looks Better Positioned?
Thermo Fisher Scientific Inc.
Abbott vs Danaher: Which Healthcare Stock Looks Better Positioned Following Earnings?
Abbott Laboratories (NYSE:ABT) delivered strong fiscal Q2 2026 results, beating quarterly estimates and raising its annual profit forecast as robust demand for its cancer diagnostics and medical devices...
Danaher Beat Earnings Estimates, so Why Are Investors Still Concerned About Growth?
Danaher Corporation (NYSE:DHR) delivered second-quarter results on July 21, marked by core growth improving compared to the previous quarter, along with disciplined execution that drove high-single-digit...
Agilent Technologies (A) Expands Its Oncology Diagnostics Reach—Can Growth Keep Up?
Agilent Technologies Inc. (NYSE:A) just extended its diagnostics franchise into one of oncology's toughest corners.
Johnson & Johnson vs. Danaher: Which Healthcare Stock Looks Better Positioned Following Earnings?
Johnson & Johnson (NYSE:JNJ) delivered strong fiscal Q2 2026 results, with sales for the quarter growing nearly 7% to $25.31 billion, above analysts' average estimate of about $25.05 billion.
Hedge Fund Resource Center